PTGS2 and breast cancer: We found that high COX2 expression (above median) in basal breast cancer is directly correlated with decreased distant metastasis free survival (DMFS) as compared to those patients with low COX2 expression (19.2 months vs 95.08 months respectively) (Figure 5A,B).